Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 197-202

  Cocchietto, M ^a   Salerno, G ^a   Alessio, E ^b   Mestroni, G ^b   Sava, G ^a  

^a Callerio Foundation   (Italy)

^b NONE

Author keywords

I.v. treatment; In vivo distribution; Ruthenium

Indexed keywords

ANTIMETASTATIC AGENT; RUTHENIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; KIDNEY; LUNG; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY FLUID COMPARTMENTS; DIMETHYL SULFOXIDE; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MICE; MICE, INBRED CBA; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; TISSUE DISTRIBUTION;

EID: 0034031914     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Giraldi T, Sava G: Selective antimetastatic drugs (review). Anticancer Res 1: 163-74, 1980.
2. Giraldi T, Sava G, Cuman R, Nisi C, Lassiani L: Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt, (±)-1,2-di(dioxopiperazin-1-yl)propane and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res 41: 2524-28, 1981.
3. AHFS Drug Information. American Society of Hospital Pharmacists 94: 572-80, 1994.
4. Cleare MJ, Hydes PC: Antitumor properties of metal complexes. In: Metal Ions in Biological Systems. New York, Marcel Dekker, 1979, pp 1-62.
5. Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M, Boccarelli A: Water soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs 1; 41-63, 1993.,
6. Sava G, Pacor S, Bregant F, Ceschia V, Mestroni G: Metal complexes of ruthenium: antineoplastic properties and perspectives. Anti-Cancer Drugs 1: 99-108, 1990.
7. Sava G. Ruthenium compounds in cancer therapy. In Metal compounds in cancer therapy. (Fricker SP, eds). London, Chapman & Hall, 1994, pp 65-91.
8. 4(DMSO) Im] on solid mouse tumors. Anti-Cancer Drugs 3: 25-31, 1992.
9. 3. Inorg Chim Acta 203: 205-17, 1993.
10. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 10: 273-80, 1992.
11. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest 8: 150-61, 1994.
12. 4(DMSO)Im] in the mouse. Clin Exp Metastasis 12: 93-100, 1994.
13. Sava G, Pacor S, Bergamo A, Mestroni G, Alessio E: Effects of ruthenium complexes on experimental tumours: irrelevance of cytotoxicity for metastasis inhibition. Chem Biol Interactions 95: 109-26, 1995.
14. Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S: Down regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an antimetastatic ruthenium complex. Int J Cancer 68: 60-66, 1996.
15. 4]. Chem-Biol Interactions 78: 223-34, 1991.
16. Mestroni G, Alessio E, Sava G: New salts of anionic complexes of Ru(III), as antimetastatic and antineoplastic agents. PCT. C 07F 15/00, A61K 31/28. WO 98/00431 08.01.98.
17. Gemelin E, Allain P, Maillart P, Turcant, A, Delva R, Lortholary A. Larra F: Long-term pharmacokinetic behavior of platinum after cisplatin administration. Cancer Chemother Pharmacol 37: 97-102, 1995.
18. Reece PA, Stafford I, Abbott RL, Anderson C, Denham J, Freeman S, Morris RG, Gill PG, Olweny CL: Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol 7: 270-5, 1989.
19. Dominici C, Petrucci F, Caroli S, Alimonti A, Clerico A, Castello MA: A pharmacokinetic study of hight-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol 7: 100-7, 1989.
20. Bogliolo GV, Lerza R, Bottino GB, Mencoboni MP, Pannacciulli IM, Vannozzi M, Fulco RA, Merlo F, Esposito M: Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer 27: 839-42, 1991.
21. Esposito M, Campora E, Repetto M, Fulco RA, Simoni GA, Falcone A, Collecchi P, Gogioso L, Nobile MT, Civalleri D: Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer. Oncology 45: 69-73, 1988.
22. Sileni VC, Fosser V, Maggian P, Padula E, Beltrame M, Nicolini M, Arslan P: Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. Cancer Chemoter Pharmacol 30: 221-5, 1992.
23. Lautersztain J, Perez-Soler R, Khokhar AR, Newman RA, Lopez-Berenstein G: Pharmacokinetics and tissue distribution of liposome-encapsuled cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II). Cancer Chemother Pharmacol 18: 93-97, 1986
24. Vadiei K, Siddik ZH, Khokar AR, al-Baker S, Sampedro F, Perez-Soler R: Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30: 365-9, 1992.
25. Nagai N, Hotta K, Yamamura H, Ogata H: Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother Pharmacol 36: 404-410, 1995.
26. Leone R, Fracasso ME, Soresi E, Cimino G, Tedeschi M, Castoldi D, Monzani V, Colombi L, Usari T, Bernareggi A: Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 29: 385-90, 1992.
27. Hudes GR, LaCreta F, Walczak J, Tinsley P, Litwin S, Comis RL, O'Dwyer PJ: Pharmacokinetic study of trinletrexate in combination whit cisplatin. Cancer research 51: 3080-3087, 1991.
28. Tamura H, Arai T: Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by tetramethylammonium hydroxide. Bunseki KagaKu 41: 13-17, 1992.
29. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G: Pharmacological control of lung metastases of solid tumours by a novel rutheniumcomplex. Clin. Expl. Metastasis 16: 371-379, 1998.
30. 4(DMSO)Im]: mechanism of action investigated on mouse tumours. Anti Cancer Drugs 10: 129-139, 1999.
31. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G: In vitro cell cycle arrest, in vivo action on solid metastasising tumours and host toxicity of the antimetastatic drug NAMI-A and of cisplatin. J Pharmacol Exp Ther 289; 559-564, 1999.
32. 4(DMSO)Im] and ruthenium uptake by tumour cells. Anticancer Drugs 7: 697-702, 1996.
33. 4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. Pathol Oncol Res 4: 30-36, 1998.